In an attempt to control drug prices in the US, the Biden administration’s proposal relies on an obscure provision of Bayh-Dole that allows the government to “march in” and relicense patents. In other words, it can take the exclusively licensed patent right from one company and grant a license to a competing firm. The provision is designed to allow the government. to step in if a company fails to commercialize a federally funded discovery and make it available to the public in a